You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SOM230

Showing 1 - 25 of 67
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Carcinoid Tumors Trial in Stanford, Tampa (Pasireotide Long Acting Release (LAR))

Active, not recruiting
Has Results
  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Pasireotide Long Acting Release (LAR)
  • Stanford, California
  • +1 more
Jan 11, 2022

Cluster Headache - Episodic and Chronic Trial in Germany, United Kingdom, United States (SOM230, Placebo)

Terminated
Has Results
  • Cluster Headache - Episodic and Chronic
  • SOM230
  • Placebo
  • Culver City, California
  • +3 more
Dec 9, 2020

Acromegaly Trial in Worldwide (Pasireotide)

Completed
Has Results
  • Acromegaly
  • Los Angeles, California
  • +9 more
Sep 1, 2021

Pasireotide s.c. in Patients With Cushing's Disease

Recruiting
  • Cushings Disease
  • SOM230
  • Phoenix, Arizona
  • +70 more
May 19, 2022

Neuroendocrine Tumors Trial in United States (Pasireotide LAR)

Completed
  • Neuroendocrine Tumors
  • Pasireotide LAR
  • Los Angeles, California
  • +3 more
Dec 17, 2020

Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Detroit (docetaxel,

Completed
Has Results
  • Adenocarcinoma of the Prostate
  • +3 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Mar 2, 2021

Cushing Disease Trial in Worldwide (Pasireotide)

Completed
Has Results
  • Cushing Disease
  • Boston, Massachusetts
  • +7 more
May 6, 2021

Thyroid Cancer Trial in Atlanta, Pittsburgh (Everolimus, Pasireotide, Everolimus and Pasireotide)

Completed
Has Results
  • Thyroid Cancer
  • Atlanta, Georgia
  • +2 more
Feb 15, 2021

Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism Trial (Pasireotide 0.6Mg Solution for Injection, Saline Solution)

Withdrawn
  • Congenital Hyperinsulinism
  • +2 more
  • Pasireotide 0.6Mg Solution for Injection
  • Saline Solution
  • (no location specified)
May 12, 2021

Pancreatic Cancer Trial in Tampa (SOM 230 LAR, Gemcitabine)

Completed
  • Pancreatic Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 25, 2020

Hepatic Cirrhosis, Alcoholism Trial in Worldwide (Pasireotide)

Completed
  • Hepatic Cirrhosis
  • Alcoholism
  • Richmond, Virginia
  • +3 more
Dec 17, 2020

Metastatic Melanoma and Merkel Cell Carcinoma Trial in Essen, Lausanne, Zuerich (Pasireotide sub-cutaneous formulation,

Completed
  • Metastatic Melanoma and Merkel Cell Carcinoma
  • Pasireotide sub-cutaneous formulation
  • Pasireotide lon acting release formulation
  • Essen, Germany
  • +2 more
Dec 17, 2020

Castration Resistant Prostate Cancer Trial in Germany (SOM230)

Completed
  • Castration Resistant Prostate Cancer
  • SOM230
  • Berlin, Germany
  • +3 more
Dec 17, 2020

Cushing's Disease, Acromegaly, Neuroendocrine Tumors Trial in Worldwide (Pasireotide, Cabergoline)

Active, not recruiting
  • Cushing's Disease
  • +8 more
  • La Jolla, California
  • +93 more
May 19, 2022

Renal Impairment Trial in Berlin, Bloemfontein (SOM230)

Completed
  • Renal Impairment
  • SOM230
  • Berlin, Germany
  • +1 more
Dec 17, 2020

Neuroendocrine Carcinoma of the Lung and Thymus Trial in Worldwide (Pasireotide LAR, Everolimus, Pasireotide LAR and Everolimus

Completed
Has Results
  • Neuroendocrine Carcinoma of the Lung and Thymus
  • Pasireotide LAR
  • +2 more
  • Aarhus, Denmark
  • +35 more
Mar 8, 2021

Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease Trial in Rochester (Pasireotide

Completed
Has Results
  • Somatostatin Analogs
  • +3 more
  • Pasireotide LAR
  • Placebo
  • Rochester, Minnesota
    Mayo Clinic
Apr 30, 2020

Cushings Disease Trial in Worldwide (Pasireotide with or without cabergoline)

Terminated
Has Results
  • Cushings Disease
  • Pasireotide with or without cabergoline
  • Birmingham, Alabama
  • +28 more
Aug 28, 2020

Post-Bariatric Hypoglycemia Trial (Pasireotide Diaspartate)

Not yet recruiting
  • Post-Bariatric Hypoglycemia
  • Pasireotide Diaspartate
  • (no location specified)
Jul 7, 2023

Cushing's Disease, Acromegaly Trial in Worldwide (Pasireotide s.c., Sitagliptin, Liraglutide)

Completed
Has Results
  • Cushing's Disease
  • Acromegaly
  • Pasireotide s.c.
  • +5 more
  • Multiple Locations, California
  • +42 more
May 7, 2019

Neuroendocrine Tumors Trial in Bad Berka, Berlin, Muenster (RAD001, SOM230)

Completed
  • Neuroendocrine Tumors
  • Bad Berka, Germany
  • +2 more
Apr 13, 2019

Carcinoid Tumor, Acromegaly Trial in Worldwide (Pasireotide)

Completed
  • Carcinoid Tumor
  • Acromegaly
  • Los Angeles, California
  • +16 more
Dec 17, 2020

Acromegaly, Pituitary Gigantism Trial in Japan (Pasireotide LAR)

Completed
Has Results
  • Acromegaly
  • Pituitary Gigantism
  • Pasireotide LAR
  • Nagoya, Aichi, Japan
  • +26 more
Aug 12, 2019

Neuroendocrine Tumors Trial in Atlanta (Pasireotide, Sir-sphere Radioembolization, Everolimus)

Completed
  • Neuroendocrine Tumors
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
Oct 16, 2018

Castrate Resistant Prostate Cancer, Chemo Naive Prostate Cancer, Prostate Cancer Trial in New Haven, Philadelphia (Pasireotide,

Terminated
Has Results
  • Castrate Resistant Prostate Cancer
  • +2 more
  • New Haven, Connecticut
  • +1 more
Apr 23, 2018